| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | GDC-0449 | GDSC1000 | pan-cancer | AAC | -0.008 | 0.8 |
| mRNA | temsirolimus | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | BRD-K16130065 | CTRPv2 | pan-cancer | AAC | 0.015 | 0.8 |
| mRNA | BRD-K03536150 | CTRPv2 | pan-cancer | AAC | -0.0081 | 0.8 |
| mRNA | AT-406 | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | 0.0074 | 0.8 |
| mRNA | GSK2126458 | GDSC1000 | pan-cancer | AAC | -0.0066 | 0.8 |
| mRNA | GSK429286A | GDSC1000 | pan-cancer | AAC | 0.0067 | 0.8 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | Bortezomib | FIMM | pan-cancer | AAC | -0.031 | 0.8 |